Bruker Corporation (BKD.F)

72.78 +0.16 (+0.22%) As of 08:09AM CEST. Market open.

Bruker Corporation

40 Manning Road
Billerica, MA 01821
United States
978 663 3660
https://www.bruker.com

Sector(s): Healthcare
Industry: Medical Devices
Full Time Employees: 9,707

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Frank H. Laukien Ph.D.	Chairman, CEO & President	1.7M	3.05M	1960
Mr. Gerald N. Herman	Executive VP & CFO	805.14k	N/A	1958
Dr. Mark R. Munch Ph.D.	Corporate Executive VP and President of Bruker Nano Group & Corporate	1.35M	N/A	1962
Mr. Juergen Srega	President of Bruker CALID Group & Bruker Daltonics Division	607.07k	N/A	1955
Dr. Falko Busse Ph.D.	President of Bruker BioSpin Group	716.24k	N/A	1967
Mr. Justin Joseph Ward	Senior Director of Investor Relations & Corporate Development	N/A	N/A	N/A
Mr. J. Brent Alldredge J.D.	General Counsel & Secretary	N/A	N/A	1975
Stacey Desrochers	Treasurer & Director of Investor Relations	N/A	N/A	N/A
Dr. Burkhard Prause Ph.D.	President and CEO of Bruker Energy & Supercon Technologies, Inc.	559.19k	N/A	1967

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.

Corporate Governance

Bruker Corporation’s ISS Governance QualityScore as of April 1, 2024 is 5. The pillar scores are Audit: 7; Board: 7; Shareholder Rights: 4; Compensation: 3.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.